A Phase 1, Single-Dose, Cross-Over Study Evaluating the Relative Bioavailability and Food Effect of a Pediatric Tablet for Oral Suspension of Bictegravir/Emtricitabine/Tenofovir Alafenamide and the Bioequivalence of a Pediatric Tablet for Oral Suspension of Emtricitabine/Tenofovir Alafenamide in Healthy Adults
Latest Information Update: 16 Jun 2021
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 16 Jun 2021 New trial record